Isocnicin and Radiotherapy: A New Hope for Glioblastoma Treatment
Author Information
Author(s): Tsafa Effrosyni, Dimitriadis Kyriakos, Kalampoki Lamprini, Papapetrou Panagiota, Georgalis Pavlos A., Bozios Georgios, Sioka Chrissa, Tsekeris Pericles, Kyritsis Athanassios P., Alexiou George A., Lazari Diamanto
Primary Institution: Neurosurgical Institute, University of Ioannina
Hypothesis
Can isocnicin enhance the effects of radiotherapy in glioblastoma treatment?
Conclusion
Isocnicin combined with radiation shows a synergistic effect in reducing glioblastoma cell viability.
Supporting Evidence
- Isocnicin significantly reduced cell viability in glioblastoma cell lines.
- Combination treatment with isocnicin and radiation increased G2/M cell cycle arrest.
- Isocnicin's IC50 values were determined to be 14 μM for U87 and 54 μM for T98 cells.
- Synergistic effects were observed in multiple combinations of isocnicin and radiation.
Takeaway
Isocnicin is a natural compound that, when used with radiation, helps fight a type of brain cancer called glioblastoma.
Methodology
Cell viability was assessed using the trypan blue exclusion assay and cell cycle distribution was analyzed using flow cytometry.
Limitations
Further studies are needed to investigate isocnicin's ability to cross the blood-brain barrier and its toxicity in normal cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website